Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab plus chemotherapy in perioperative treatment of resectable locally advanced head and neck squamous carcinoma
ChiCTR2400086333Phase 2Not yet recruiting
- Sponsor
- Shanxi Cancer Hospital
- Start
- Jun 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adebrelimab in head and neck squamous cell carcinoma (HNSCC), sponsored by Shanxi Cancer Hospital. Primary endpoint: Major pathological response. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
adebrelimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ChiCTR2400086333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400086333.